Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Aditya Bardia, MD, MPH, on Clinical Implications of Prescribing Sacituzumab Govitecan for Triple-Negative Breast Cancer

Posted: Monday, October 19, 2020

Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses the positive phase III ASCENT trial results and what clinicians need to bear in mind when prescribing the antibody-drug conjugate sacituzumab govitecan-hziy for patients with previously treated metastatic triple-negative breast cancer.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.